Endo webcast - Jefferies ConferenceI will provide the response to this question / clarification request below when I receive it...
----- Original Message -----
From:
Sent: Wednesday, October 06, 2010 7:00 AM
Subject: Mr. Davis...appreciate clarification re statement by Dr. Gergel...
...on this morning's webcast of Endo's presentation at the Jefferies 2010 Global SpecPharma and European Healthcare Conference.
Re: Pipeline developments with specific reference to Urocidin
Mr. Gergel made the statement... "we're analyzing data from the current Urocidin study and expect to complete that effort over the next few months.
I have bolded the above timeframe "over the next few months" as I was under the assumption it would be completed by September 30 based on this recent release by Bioniche Life Sciences Inc. which stated...
"We're preparing to initiate a large study with Urocidin in the second half of this year that could become the pivotal study of this very interesting product to treat bladder cancer," said Dr. Ivan Gergel, Executive Vice President, Research and Development at Endo Pharmaceuticals Inc. "Urocidin is a novel treatment for refractory bladder cancer, which represents the type of innovative solutions we want to offer urologists and their patients."
Concurrently, 12-month data from the ongoing U.S. Food and Drug Administration (FDA) Phase III registration trial with Urocidin(TM) for non-muscle-invasive bladder cancer refractory to current therapy are undergoing thorough analysis. Endo expects to complete this process by the end of September, 2010. (issued August 19, 2010, Bioniche NR)
Realistically, when is the analysis of the Urocidin ttrial data expected to be completed by? And, very important to long-standing shareholders of Bioniche, when will Endo/ Bioniche communicate an update on this analysis?
In a release from Bioniche as recent as September 27 it reads "disclosure concerning FDA Phase III Fast Track clinical trial with Urocidin....Such disclosure is expected to become available within the next several weeks".
Request: Please confirm that the final statement/ line in above paragraph is still accurate. And, as time has already past since the Sep 27-10 release, can you now be more specific on the timing of this disclosure.
Appreciate your attention to this matter and thank you in advance for a prompt reply.
Individual investor, shareholder of Bioniche Life Sciences